Nsf Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 21-06-2024
- Paid Up Capital ₹ 7.28 M
as on 21-06-2024
- Company Age 17 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.23 Cr
as on 21-06-2024
- Revenue 32.87%
(FY 2021)
- Profit 75.91%
(FY 2021)
- Ebitda 6.20%
(FY 2021)
- Net Worth 7.42%
(FY 2021)
- Total Assets -5.01%
(FY 2021)
About Nsf Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.28 M.
The company currently has active open charges totaling ₹1.23 Cr.
Humera Jabeen, Farhana Begum, and Mohammed Saleem serve as directors at the Company.
- CIN/LLPIN
U24232TG2007PTC052291
- Company No.
052291
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jan 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nsf Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Saleem  | Managing Director | 06-Jan-2007 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Humera Jabeen | Director | 23-Jan-2020 | Current |
| Farhana Begum | Nominee Director | 06-Jan-2007 | Current |
Financial Performance of Nsf Pharma.
Nsf Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 32.87% increase. The company also saw a substantial improvement in profitability, with a 75.91% increase in profit. The company's net worth moved up by a moderate rise of 7.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nsf Pharma?
In 2021, Nsf Pharma had a promoter holding of 70.00% and a public holding of 30.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 23 Nov 2020 | ₹7.50 M | Open |
State Bank Of Hyderabad Creation Date: 05 Jun 2010 | ₹4.80 M | Open |
How Many Employees Work at Nsf Pharma?
Nsf Pharma has a workforce of 3 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nsf Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nsf Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
